Indeed, CDER Acting Director Michael Davis reinforced the policy point publicly on X, emphasizing that compounded GLP1 products are not FDAapproved and have not undergone the rigorous review for safety, efficacy, and manufacturing quality that is required for drugs approved through the new drug application (NDA) or abbreviated new drug application (ANDA) pathways.[3] This is now the third major set of warning letters in less than a year with the majority aimed at telehealth marketing of compounded GLP-1 products: September 2025: roughly 80 warning letters and 40 untitled letters March 2026: 30 warning letters June 2026: 25 warning letters The Claims FDA Is Targeting As in earlier rounds, the June 2026 letters appear highly standardized and focus on consumerfacing promotion of compounded GLP-1 products
They both work similarly, but there are a few key differences between them that may help you decide which is right for your health journey
These patterns often resurface if medication is stopped or when challenges arise, which is why understanding both the biological effects of medication and the behavioral side of eating is so important
Related Reading Glp 1 Medications Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications Maximus Glp 1 Medical and Editorial Standards Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims
The dose may be increased again to 14 mg once daily if additional glycemic control is needed after 30 days of treatment with the 7-mg dose
This simple habit can seriously boost your metabolic health and support your weight loss journey, proving that *when* you eat can be as important as *what* you eat
